This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by May, C. W. Articles by Diaz, M. N. Search for Related Content PubMed PubMed Citation Articles by May, C. W. Articles by Diaz, M. N. Related Collections Cardio-renal physiology/pathophysiology Other heart failure Other Treatment

Challenges for the Basis of Practice

The Role of Digoxin in the Treatment of Heart Failure

Christopher W. May, MD and Marco N. Diaz, MD

From the Division of Cardiac Services, Maine Medical Center, Portland, Me.

Correspondence to Christopher W. May, MD, Division of Cardiac Services, Maine Medical Center, 22 Bramhall Street, Portland, Maine 04102. E-mail cmay0001@maine.rr.com

Key Words: heart failure • digoxin • treatment

An extract of the first 250 words of the full text is provided, because this article has no abstract.

Digoxin and diuretics were once the cornerstones of therapy for patients with chronic heart failure. During the past 2 decades, an increasing number of therapeutic options for the treatment of symptomatic heart failure has emerged. Demonstrated benefit of these therapies has led to parallel growth of practice guidelines and performance measures. As a result, physicians caring for patients with heart failure face the increasing challenge of introducing and titrating multiple medications to achieve the perceived benefit promised by clinical trials while adhering to guideline-driven treatment algorithms.

The role of digoxin in the treatment of heart failure is long and storied, with the Digitalis Investigation Group (DIG) trial a relatively recent addition.¹ Currently, the addition of digoxin for the treatment of stage C heart failure is a 2B (level of evidence B) recommendation.² The DIG trial itself is still undergoing reinterpretation, particularly for subgroups defined by gender or clinical severity. However, the patients in the DIG trial may no longer reflect the heart failure population today, which has been reshaped by β-blockers, aldosterone antagonists, and devices to resynchronize contraction and prevent sudden death. Furthermore, the serum digoxin concentrations of many of the patients in the DIG study exceeded current recommendations. With this in mind, when should digoxin be added to the treatment of patients with decompensated systolic heart failure? Should dosing be guided by digoxin serum concentrations? Clinical studies have suggested increased hospitalizations and all-cause mortality when discontinuing chronic digoxin therapy in stable patients. Once started, when should digoxin be discontinued . . . [Full Text of this Article]